Salts and solid forms of elenestinib
AssigneeAssia Chemical Industries Ltd.
InventorsValentina Travancic, Dijana Škalec Šamec
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses salts and solid-state forms of Elenestinib, processes for preparation thereof and pharmaceutical compositions thereof.
Claims21
A crystalline form of Elenestinib camsylate.
(canceled)
A crystalline Form S1 of Elenestinib succinate, which is characterized by data selected from one or more of the following:
- i. an XRPD pattern having peaks at 4.6, 11.9, 13.7, 19.6 and 20.9 degrees 2-theta±0.2 degrees 2-theta;
- or
- ii. an XRPD pattern as depicted in FIG. 2.
A crystalline Form F1 of Elenestinib:fumaric acid, which is characterized by data selected from one or more of the following:
- i. an XRPD pattern having peaks at 4.6, 9.2, 12.1, 13.9 and 18.5 degrees 2-theta±0.2 degrees 2-theta;
- or
- ii. an XRPD pattern as depicted in FIG. 4.
A crystalline Form P1 of Elenestinib phosphate, which is characterized by data selected from one or more of the following:
- i. an XRPD pattern having peaks at 4.0, 16.4 and 21.5 degrees 2-theta±0.2 degrees 2-theta;
- or
- ii. an XRPD pattern as depicted in FIG. 8.
(canceled)
(canceled)
18-22. (canceled)
Dependencies are inferred from the claim text.